Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole.
The present report illustrates the clinical and biochemical outcome in two amiodarone iodine-induced thyrotoxicosis (AIIT) patients submitted to plasmapheresis. Amiodarone was discontinued, and treatment with MMI (40 mg/day) was started. In addition, patients were submitted to two sessions of plasma-exchange, with a one-day interval between the two session. In both patients serum total T3 (TT3) and free T3 (FT3) concentrations decreased promptly but in contrast to the serum TT3, FT3 levels remained steadily above the normal range. A similar behaviour was observed for total T4 and free T4 plasma concentrations. Interestingly, a clearcut clinical amelioration was observed in both patients even before a reduction of circulating free thyroid hormone concentrations could be documented. In conclusion, our experience indicates that plasmapheresis may be useful in order to obtain a rapid amelioration of severe clinical picture of thyrotoxicosis, but cannot be considered as a definite therapy in AIIT. It should be considered that plasmapheresis is not devoid of risks and is also a very expensive procedure.
Aghini-Lombardi
F
F
Istituto di Endocrinologia, University of Pisa, Italy.
Mariotti
S
S
Fosella
P V
PV
Grasso
L
L
Pinchera
A
A
Braverman
L E
LE
Martino
E
E
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D010956:Plasmapheresis; D013971:Thyrotoxicosis / Q000139:chemically induced / Q000188:drug therapy / Q000628:therapy*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D008713:Methimazole; D000638:Amiodarone; D013974:Thyroxine